Two New FDA-Approved Treatments for RKD

FILSPARI® (sparsentan) has been FDA approved for FSGS, and TRUTAKNA® (atacicept) has been FDA approved for IgAN. More information is coming soon. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Current Partnerships

Thank you to all of our Corporate Partners for your support of NephCure and our mission to empower people affected by rare, protein-spilling kidney diseases, while leading the revolution in research and care.

Interested in partnering with us? Email Britta Dornan, executive director of strategic relations, at bdornan@nephcure.org. Read about the current partnership terms and guidelines

Presenting Sponsor

Platinum Sponsor

Gold

Silver Sponsor

Memberships

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.